康蒂尼药业

Beijing Contine Pharmaceutical is a commercial-stage biopharmaceutical company headquartered in Beijing, China, focusing on the development of treatments for organ fibrosis and other rare diseases. The company achieved significant recognition as the first to bring an idiopathic pulmonary fibrosis (IPF) treatment, Etuary (pirfenidone), to the Chinese market. Contine's research and development efforts are primarily centered on small molecule therapeutics, with its lead candidate F351 (hydronidone) currently in Phase 3 trials for hepatitis B-induced liver fibrosis. As a majority-owned subsidiary of the GNI Group, the company benefits from a global R&D network and has established a strong commercial presence in the Chinese respiratory and hepatology markets. Contine continues to expand its pipeline to address unmet needs in connective tissue disease-associated interstitial lung disease and acute liver failure.